hims semaglutide reviews Hims? Hers? It's Novo Nordisk's Market Now Hims vs Ro Weight Loss

Daniel Uba, MD Published Jun 9, 2026 13 min read The semaglutide patent expiry biosimilar question is no longer hypothetical

Supply reliability has been a frequent pain point in the GLP-1 space over the past three or four years, with unprecedented demand exceeding manufacturing capacity and resulting in years-long drug shortages across US and Europe

Disclaimer: This guide is for educational purposes only and does not replace official ICD-10-CM guidelines, your organizations compliance policies, or advice from a certified coding professional

Medicare spending on GLP-1s has surged, raising concerns about long-term affordability and access 2

Furthermore, dedicated cardiovascular outcome trials (LEADER, SUSTAIN-6, REWIND)[26, 28, 29] have demonstrated consistent reduction in major adverse cardiovascular events with long-acting GLP-1 RAs, particularly in people with established ASCVD

Once you decide youre ready to stop taking Semaglutide, well taper your dose over a few weeks